Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthcare company Bod Australia (BDA) has announced a collaboration with the University Of South Australia’s School of Pharmacy and Medical Sciences
  • This partnership will see the organisations study the effects of Bod’s MediCabilis product on patients
  • The research will assist in ongoing product development initiatives as well as pave the way for future research
  • The company is confident that findings from the partnership will assist clinicians and prescribers in gaining a stronger understanding of MediCabilis
  • Bod Australia is down 2.86 per cent today with shares trading for 34 cents each

Bod Australia (BDA) has entered a research collaboration with the University of South Australia (UniSA) for Bod’s MediCabilis cannabis product.

As part of the collaboration, the parties will study MediCabilis and its effects on patients.

Bod is a healthcare company focused on exploring and developing healthy and beauty products derived from plant-based extracts and hemp.

The research will assist in ongoing product development initiatives as well as pave the way for future research.

The collaboration will be conducted with researchers from UniSA’s nationally-renowned School of Pharmacy and Medical Sciences

“This research will provide valuable information to facilitate further product development and guide clinical utility,” UniSA Senior Research Fellow Dr Stephanie Reuter Lange said.

Bod CEO Jo Patterson is also pleased with securing a collaboration with a high-quality organisation.

“[This] provides tremendous validation of our approach to date and ongoing commitment to R&D, building IP and generating revenue,” Jo said.

Results from the collaboration is set to lay a strong foundation for further research with Bod’s exclusive extract.

The company is confident that findings from the partnership will assist clinicians and prescribers in gaining a stronger understanding of MediCabilis.

Bod Australia is down 2.86 per cent today with shares trading for 34 cents each at 3:49 pm AEDT.

BDA by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening